Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma

Annals of Allergy, Asthma and Immunology

Volumn 95, Issue 3, 2005, Pages 283-290

  Lipworth, Brian J ^a   Sims, Erica J ^a   Das, Sudip K ^b   Morice, Alyn H ^c   O'Connor, Brian J ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Innovata Biomed Ltd   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE;

ADULT; ARTICLE; ASTHMA; BRONCHOPROTECTION; BRONCHUS REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DIAGNOSTIC VALUE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DOUBLING DILUTION DIFFERENCE; DRUG DELIVERY SYSTEM; DRY POWDER; FEMALE; HUMAN; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 25444492318     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61226-4     Document Type: Article

References (23)

1. National Asthma Education and Prevention Program. Expert Panel: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol. 2002;110:S141-S219.
2. Young LY, Koda-Kimble MA, Guglielmo BJ. Handbook of Applied Therapeutics. 6th ed. Vancouver,WA: Applied Therapeutics Inc; 1996.
3. Van der Palen J. Peak inspiratory flow through Diskus and Turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respir Med. 2003;97:285-289.
4. Barrowcliffe J, McGlynn P, Tickle S, Sandbank F, Wong T. The in vitro evaluation of a novel multi-dose dry powder inhaler. In: Drug Delivery to the Lungs VII. Bristol, England: The Aerosol Society; 1996:82-85.
5. Newhouse MT, Nantel NP, Chambers CB, Pratt B, Parry-Billings M. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest. 1999;115:952-956.
6. 2-agonist. Am J Respir Crit Care Med. 1999; 160:354-357.
7. Inman MD, Hamilton AL, Kerstjens HAM, Watson RM, O'Byrne PM. The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J Allergy Clin Immunol. 1998;101:342-348.
8. Anderson GP. Pharmacology of formoterol: an innovative bronchodilator. Agents Actions. 1991;34(suppl):97-115.
9. Ahrens RC, Hendeles L, Clarke WR, et al. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. Am J Respir Crit Care Med. 1999;160:1238-1243.
10. Newhouse MT, Patel P, Parry-Billings M. Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler DPI. Eur Respir J. 2003;21:816-820.
11. Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G. Assessment of a relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Eur J Clin Pharmacol. 2002;58:S61-S67.
12. Lipworth BJ, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med. 1998;104:431-438.
13. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10:2484-2489.
14. Lötvall J, Mellén A, Arvidsson P, et al. Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler. Can Respir J. 1999;6:412-416.
15. Pearlman DS, Chervinsky P, Laforce C, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med. 1992;327:1420-1425.
16. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med. 2000;161:309-329.
17. Lipworth BJ, McDevitt DG. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 1989;36:239-245.
18. 2-adrenoceptor-mediated responses to inhaled salbutamol. Br J Clin Pharmacol. 2001;51:359-362.
19. Bremner P, Burgess C, Beasley R, et al. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med. 1992;86:419-423.
20. 2-agonists in the management of asthma. Drug Safety. 1992;7:54-70.
21. American Thoracic Society. Standardization of spirometry: update. Am Rev Respir Dis. 1987;136:1285-1298.
22. Lipworth BJ, Newnham DM, Clark RA, Dhillon DP, Winter JH, McDevitt DG. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax. 1995;50:54-61.
23. 2-adrenoceptor polymorphism. Chest. 2000;118:321-328.